Ownership
Private
Employees
~100
Stage
Preclinical
Modalities
Autologous cell therapyGene therapyCAR T cell therapy (CAR-T)

Miltenyi Biomedicine General Information

Newly established biopharmaceutical company developing cell and gene therapies, focusing on difficult-to-treat hematological cancers using CAR T technology

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Bergisch Gladbach,
Germany

Drug Pipeline

No pipeline data available

For full access to Miltenyi Biomedicine's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Miltenyi Biomedicine Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Miltenyi Biomedicine's complete valuation and funding history, request access »